[go: up one dir, main page]

TR201907804T4 - Apaf-1 inhibitör bileşikleri. - Google Patents

Apaf-1 inhibitör bileşikleri. Download PDF

Info

Publication number
TR201907804T4
TR201907804T4 TR2019/07804T TR201907804T TR201907804T4 TR 201907804 T4 TR201907804 T4 TR 201907804T4 TR 2019/07804 T TR2019/07804 T TR 2019/07804T TR 201907804 T TR201907804 T TR 201907804T TR 201907804 T4 TR201907804 T4 TR 201907804T4
Authority
TR
Turkey
Prior art keywords
apaf
inhibitor compounds
piperazinedione
prophylaxis
apoptosis
Prior art date
Application number
TR2019/07804T
Other languages
English (en)
Inventor
Messeguer Peypoch Àngel
Moure Fernández Alejandra
González Pinacho Daniel
Masip Masip Isabel
Perez Payá Enrique
Garcia Villar Natividad
Monlleó Mas Ester
Catena Ruiz Juanlo
Original Assignee
Spiral Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spiral Therapeutics Inc filed Critical Spiral Therapeutics Inc
Publication of TR201907804T4 publication Critical patent/TR201907804T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)

Abstract

Formül (I)'e sahip 2,5-piperazinedionun türevleri, apoptotik peptidaz aktive edici faktör 1 (Apaf-1) inhibitörleridir, bu nedenle apoptozdaki artışla ilişkili bir patolojik ve/veya fizyolojik durumun profilaksisi ve/veya tedavisi için aktif farmasötik bileşenler olarak faydalıdırlar.
TR2019/07804T 2009-07-30 2010-07-29 Apaf-1 inhibitör bileşikleri. TR201907804T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200901757 2009-07-30

Publications (1)

Publication Number Publication Date
TR201907804T4 true TR201907804T4 (tr) 2019-06-21

Family

ID=43529761

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07804T TR201907804T4 (tr) 2009-07-30 2010-07-29 Apaf-1 inhibitör bileşikleri.

Country Status (15)

Country Link
US (1) US9040701B2 (tr)
EP (1) EP2460798B1 (tr)
JP (1) JP5694320B2 (tr)
KR (1) KR101786761B1 (tr)
CN (1) CN102574818B (tr)
AU (1) AU2010277505B2 (tr)
BR (1) BR112012002134B8 (tr)
CA (1) CA2769408C (tr)
EA (1) EA021838B1 (tr)
ES (1) ES2727711T3 (tr)
IN (1) IN2012DN01378A (tr)
MX (1) MX2012001339A (tr)
NZ (1) NZ598125A (tr)
TR (1) TR201907804T4 (tr)
WO (1) WO2011012746A2 (tr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1912679A4 (en) 2005-06-15 2009-07-29 Massachusetts Inst Technology AMINOUS LIPIDS AND ITS USES
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
ES2666559T3 (es) 2009-12-01 2018-05-07 Translate Bio, Inc. Entrega del mrna para la aumentación de proteínas y enzimas en enfermedades genéticas humanas
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology POLY (BETA AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
DK2691443T3 (da) 2011-03-28 2021-05-03 Massachusetts Inst Technology Konjugerede lipomerer og anvendelser af disse
BR112013031553A2 (pt) 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
NZ747501A (en) * 2011-10-27 2020-05-29 Massachusetts Inst Technology Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
ES2443538B1 (es) * 2012-07-19 2014-11-26 Consejo Superior De Investigaciones Cientificas (Csic) Compuestos beta-lactámicos inhibidores de APAF1
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
WO2014153052A2 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
EP4446413A3 (en) 2013-03-14 2024-12-18 Translate Bio, Inc. Methods for purification of messenger rna
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
AU2014340155B2 (en) 2013-10-22 2018-11-01 Massachusetts Institute Of Technology Lipid formulations for delivery of messenger RNA
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
CN105658242A (zh) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 用于苯丙酮尿症的mrna疗法
CN106164248B (zh) 2014-04-25 2019-10-15 川斯勒佰尔公司 信使rna的纯化方法
CN106659731A (zh) 2014-05-30 2017-05-10 夏尔人类遗传性治疗公司 用于递送核酸的可生物降解脂质
JP6599373B2 (ja) 2014-06-24 2019-10-30 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための立体化学的に濃縮した組成物
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
HRP20230494T1 (hr) 2015-06-19 2023-08-04 Massachusetts Institute Of Technology Alkenil supstituirani 2,5-piperazindioni i njihova upotreba u pripravcima za isporuku sredstva subjektu ili stanici
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
US11273295B2 (en) 2018-04-19 2022-03-15 Spiral Therapeutics, Inc. Inner ear drug delivery devices and methods of use
KR20210060480A (ko) 2018-08-24 2021-05-26 트랜슬레이트 바이오 인코포레이티드 전령 rna의 정제 방법
CA3120647A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
CN113766939B (zh) 2019-02-25 2025-07-08 斯皮拉尔诊疗有限公司 用于输送药物的鼓室内注射器装置和针以及使用方法
JP7661346B2 (ja) 2020-01-24 2025-04-14 スパイラル・セラピューティクス・インコーポレイテッド 外科用顕微鏡システム
EP4137131A1 (en) * 2021-08-17 2023-02-22 Centre National de la Recherche Scientifique (CNRS) Novel serotonin analogues and their uses for treating iron-associated disorders
CN115124449B (zh) * 2022-05-24 2024-02-02 上海英诺富成生物科技有限公司 一种吲哚化合物及制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560503A (en) * 1968-09-18 1971-02-02 Council Scient Ind Res Di-lower alkyl-substituted octahydropyrazinopyrimidinones
GB1284582A (en) * 1969-11-10 1972-08-09 Council Scient Ind Res Substituted piperazinopyrimidinones
JPH04234375A (ja) * 1990-12-27 1992-08-24 Ajinomoto Co Inc 新規２，５−ジオキソピペラジン化合物及びその製造法
HUT68769A (en) * 1991-05-07 1995-07-28 Merck & Co Inc FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
JPH05117246A (ja) * 1991-10-23 1993-05-14 Ajinomoto Co Inc 新規２，５−ジオキソピペラジン化合物とその製造法及びα−Ｌ−アスパルチル−Ｌ−フエニルアラニンメチルエステル誘導体の製造法
WO1996000391A1 (en) * 1994-06-23 1996-01-04 Affymax Technologies N.V. Methods for the synthesis of diketopiperazines
WO2002070493A1 (en) * 2001-01-19 2002-09-12 Pharmacopeia, Inc. Bisaryl derivatives having fsh receptor modulatory activity
EP1571970B1 (en) * 2002-10-02 2011-08-17 DMI Biosciences, Inc. Diagnosis and monitoring of diseases
WO2005052177A1 (ja) * 2003-11-28 2005-06-09 Kyowa Hakko Kogyo Co., Ltd. ジペプチドの製造法
ES2296484B1 (es) * 2005-11-23 2009-04-01 Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) Composicion farmaceutica para inhibir la apoptosis.
ES2293834B1 (es) * 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.

Also Published As

Publication number Publication date
NZ598125A (en) 2014-05-30
CA2769408A1 (en) 2011-02-03
EP2460798A4 (en) 2013-02-27
MX2012001339A (es) 2012-03-07
JP5694320B2 (ja) 2015-04-01
BR112012002134B8 (pt) 2021-05-25
AU2010277505A1 (en) 2012-03-08
AU2010277505B2 (en) 2016-01-14
WO2011012746A3 (es) 2011-07-14
ES2727711T3 (es) 2019-10-18
BR112012002134A2 (pt) 2016-05-31
JP2013500314A (ja) 2013-01-07
KR20120052354A (ko) 2012-05-23
CA2769408C (en) 2017-09-05
EA201270215A1 (ru) 2012-11-30
BR112012002134B1 (pt) 2021-03-02
EA021838B1 (ru) 2015-09-30
IN2012DN01378A (tr) 2015-06-05
CN102574818B (zh) 2015-02-25
KR101786761B1 (ko) 2017-10-18
WO2011012746A2 (es) 2011-02-03
US20120122868A1 (en) 2012-05-17
EP2460798B1 (en) 2019-02-27
US9040701B2 (en) 2015-05-26
EP2460798A2 (en) 2012-06-06
CN102574818A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
TR201907804T4 (tr) Apaf-1 inhibitör bileşikleri.
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
UA97834C2 (ru) Производные сульфониламида для лечения анормального роста клеток
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
EA201201665A1 (ru) Новые соединения
EA201000098A1 (ru) Производные хиназолинамида
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
MX2010006241A (es) Derivados de aminotriazol como agonistas de alx.
EA201270535A1 (ru) Пуриновые производные, применимые в качестве ингибиторов hsp90
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
EA201170832A1 (ru) Пуриновые соединения
EA200801997A1 (ru) Новые соединения
EA200901473A1 (ru) Внутривенные и пероральные лекарственные формы прямого и обратимого ингибитора p2y12
UA107784C2 (en) Inhibitor of melanin production
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
EA201100872A1 (ru) Производные хиназолинамида
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
MA33848B1 (fr) Dérivés sulfonamides hétérocycliques
ATE481395T1 (de) Cyclohexylderivate